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Current treatments to control pathological or unwanted immune
responses often use broadly immunosuppressive drugs. New
approaches to induce antigen-specific immunological tolerance
that control both cellular and humoral immune responses are
desirable. Here we describe the use of synthetic, biodegradable
nanoparticles carrying either protein or peptide antigens and
a tolerogenic immunomodulator, rapamycin, to induce durable
and antigen-specific immune tolerance, even in the presence of
potent Toll-like receptor agonists. Treatment with tolerogenic
nanoparticles results in the inhibition of CD4+ and CD8+ T-cell
activation, an increase in regulatory cells, durable B-cell tolerance
resistant to multiple immunogenic challenges, and the inhibition
of antigen-specific hypersensitivity reactions, relapsing experi-
mental autoimmune encephalomyelitis, and antibody responses
against coagulation factor VIII in hemophilia A mice, even in
animals previously sensitized to antigen. Only encapsulated rapa-
mycin, not the free form, could induce immunological tolerance.
Tolerogenic nanoparticle therapy represents a potential novel ap-
proach for the treatment of allergies, autoimmune diseases, and pre-
vention of antidrug antibodies against biologic therapies.
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Undesired immunogenicity can have a profound impact onhuman health. Allergies, including allergic asthma and se-
vere food allergies, affect ∼20% of the population, and the
prevalence has been steadily increasing over the past several
decades (1). The prevalence of autoimmune diseases, including
multiple sclerosis and type 1 diabetes, is ∼4.5% (2). Unwanted
immunogenicity can also affect both efficacy and safety of bio-
logic drugs (3), particularly in the case of protein replacement
therapies for the treatment of genetic deficiencies, such as he-
mophilia A (4) and Pompe Disease (5). Immunomodulatory
agents commonly used to control immunogenicity are often
broadly immunosuppressive and typically require chronic ad-
ministration that can lead to reactivation of latent pathogens, de-
velopment of tumors, and opportunistic infections (6, 7). Therefore,
antigen-specific, durable tolerogenic therapy would be highly de-
sirable from an efficacy and safety perspective.
Multiple techniques for antigen-specific immunotherapy have
been described, although only allergen immunotherapy, wherein
low doses of antigen are delivered in the absence of immuno-
modulating agents, is currently used in the clinic (1). Experi-
mental approaches have included oral administration of antigen,
high dose tolerance, and the use of altered peptide ligands (8).
Although these methods have been successful in preclinical
models, translation to human clinical trials has been largely
disappointing (8). Alternative strategies to leverage tolerogenic
programming associated with apoptotic cells include conjugating
antigen to splenocytes (9–12) or synthetic microparticles (13, 14)
or targeting antigen to the surface of red blood cells (15). Other
approaches include loading particles with MHC complexes that
present relevant peptides in the absence of costimulation (16,
17), liposomal copresentation of antigen with a ligand specific
for the negative signaling receptor CD22 on B cells (18), code-
livery of peptide antigen with an aryl hydrocarbon receptor ag-
onist (19), and cotreatment with pharmacological agents, such as
methotrexate (20). A major concern for antigen immunotherapy
is the ability to induce and maintain tolerance in the presence of
proinflammatory stimuli caused by tissue stress, injury, or con-
current infections. We sought to develop an antigen-specific
tolerogenic technology that could control both T-cell– and
B-cell–mediated immunity and that was durable over time and to
multiple challenges with the antigen, even in the presence of
strong innate immune stimulants.
Dendritic cells (DCs) are an attractive target for immuno-
therapies due to their central role in antigen presentation to T
cells and their ability to induce and control regulatory responses
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to secure self-tolerance (21–25). Thomson and colleagues (26,
27) demonstrated that treating DCs with rapamycin, an inhibitor
of the mTOR pathway, induces a tolerogenic DC phenotype
capable of inducing Treg differentiation and antigen-specific
immune tolerance that is resistant to the proinflammatory cas-
cade triggered by TLR signaling. However, conventional therapy
with free rapamycin requires chronic systemic administration,
resulting in broad immunosuppression due to its direct effect on
lymphocytes (28), whereas low doses of rapamycin may para-
doxically augment effector T-cell memory (29). Thus, it would be
desirable to transiently target rapamycin’s effects to DCs and
other antigen-presenting cells (APCs) at the time of antigen en-
counter. Nanoparticles (NPs) are an ideal mechanism to deliver
antigen (16, 30, 31) and drugs (32) to APCs, as these cells are
keyed to capture and internalize nanoparticulates such as viruses.
Here we describe the development of tolerogenic NPs (tNPs)
using materials and compounds that have been well validated in
the clinic. These self-assembling, biodegradable poly(lactide-
coglycolide) (PLGA) tNPs containing either protein or peptide
antigens and rapamycin are capable of inducing durable antigen-
specific tolerance that control adaptive immune responses and
withstand multiple immunogenic challenges with antigen. We
demonstrate that either s.c. or i.v. administration of tNPs inhibits
the activation of antigen-specific CD4+ and CD8+ T cells and B
cells while inducing antigen-specific Tregs and Bregs. Swiss Jack
Lambert (SJL) mice immunized with the myelin proteolipid
protein 139–151 peptide in complete Freud’s adjuvant (PLP139–
151/CFA) and treated therapeutically with a single dose of tNPs
at the peak of disease are completely protected from developing
relapsing paralysis. In hemophilia A animals, administration of
tNP before or after the establishment of an anti-factor VIII
(FVIII) antibody response led to a significant reduction of the
neutralizing antibody response against FVIII. Treatment of mice
with tNP prevents both cellular and humoral immunity even in
the presence of potent TLR agonists. These effects are de-
pendent on the presence of the encapsulated rapamycin (not free
in solution).
Results
Induction of CD4+ T-Cell Tolerance Using tNPs. PLGA tNPs con-
taining rapamycin and chicken ovalbumin (OVA) or rapa-
mycin and the MHC class II-restricted OVA peptide 323–339
(OVA323–339) were prepared using a water-in-oil-in-water double
emulsion process (Fig. 1A). To investigate whether tNPs could
inhibit CD4+ T-cell activation, T cells specific for the OVA323–339
peptide (OTII T cells) were adoptively transferred into naive
animals. Mice were then immunized s.c. with OVA323–339 admixed
with a TLR7/8 agonist, R848, and concomitantly treated i.v. with
tNP or control NPs. Four days postimmunization, the number of
OTII T cells in the draining popliteal lymph node (popLN) of
animals that were immunized but not treated was ∼6.5-fold
greater than that of their naïve, unimmunized counterpart (Fig.
1B). The i.v. administration of tNPs completely abrogated the
proliferation of OTII T cells, whereas empty NPs admixed with
OVA323–339 peptide had little effect. Of note, in these experi-
ments, the tNP treatment was administered i.v., whereas the
immunization was provided locally by s.c. administration. To test
the direct, local effect of tNP treatment, subsequent experiments
evaluated s.c. administration of tNPs (Fig. 1C). Control NPs
containing OVA323–339 only (NP[OVA323–339]) induced the ac-
tivation and proliferation of OTII T cells in the draining popLN,
whereas no expansion was observed after treatment with tNP
containing rapamycin and OVA323–339. However, an increase in
the percentage of Foxp3+CD25+ OTII T cells was evident after
tNP treatment, indicating induction of T regulatory cells. Un-
expectedly, the opposite trends were observed when an equiva-
lent amount of free rapamycin (10 μg) was admixed with NP
[OVA323–339] (Fig. 1C). These results suggest that administration
of tNP led to the formation of MHC class II-restricted regulatory
T cells that inhibited the activation of CD4 T-cell immunity and
that codelivery of antigen with encapsulated rapamycin was
critical. To avoid the possible direct suppressive activity of
residual encapsulated rapamycin on CD4 T-cell activation, mice
were treated i.v. with tNP 6 d before the OTII T-cell transfer to
allow time for the inhibitory effect of rapamycin to dissipate
(Fig. 1D). Immunized animals without previous treatment
showed robust accumulation of the OTII T cells following im-
munization with free OVA323–339+R848 s.c. (Fig. 1D). Treat-
ment of mice with tNP before OTII T-cell transfer and im-
munization inhibited the subsequent expansion of OTII T cells,
whereas injections of control NPs containing rapamycin only
(NP[Rapa]) had little to no effect. These results indicate that
administration of tNP can suppress CD4+OTII T-cell responses
through the induction of endogenous MHC class II-restricted
suppressive cells.
Inhibition of Humoral Immunity by tNP. We next investigated the
effect of tNP treatment during the development of a humoral
response. Mice immunized s.c. with an admix of OVA and
a TLR9 agonist, CpG oligonucleotides (OVA+CpG), showed
a mounting antibody response with increasing anti-OVA titers
with each successive boost (Fig. 2 A and B). Concomitant
treatment with tNP administered either s.c (Fig. 2A) or i.v. (Fig.
2B) inhibited the anti-OVA antibody response, even when the
tNPs were admixed with CpG (Fig. 2A). The inhibition of the
humoral response was dependent on the encapsulation of rap-
amycin, as providing the OVA323–339 peptide alone in free or
encapsulated form (NP[OVA323–339]) or just free rapamycin (all
admixed to OVA+CpG) did not affect the anti-OVA response
(Fig. 2A). Importantly, both peptide- and protein-containing
tNPs were similarly efficacious (Fig. 2B, Left and Middle panels,
respectively). In contrast, control NP[OVA] administered s.c.
or i.v. enhanced the humoral response (Fig. 2B, Right).
We next evaluated splenic B-cell activation and function in
mice immunized i.v. with an immunogenic particulate form of
OVA (pOVA). Approximately 10–12% of B cells (B220+) found
in the local draining LN acquired a typical germinal center
phenotype, expressing low levels of IgD, high levels of GL7, and
the proliferation marker Ki67 (Fig. 2C). In contrast, when ani-
mals were concomitantly administered tNP (containing rapa-
mycin+OVA323–339) s.c., the proportion of activated germinal
center B cells was similar to or below the levels found in naïve
animals. To determine the impact of tNP treatment directly on
B cells, B cells from MD4 B-cell receptor (BCR) transgenic
animals were adoptively transferred into CD45.1+ animals. The
transgenic BCR is specific for hen egg lysozyme (HEL), and the
presence of this protein results in cell activation of MD4 B cells
in vivo and in vitro (33). HEL-only particles injected i.v. induced
the activation of MD4 B cells in the spleen 4 d later, however
providing tNP containing similar amounts of HEL (together with
rapamycin) did not (Fig. 2D). These results show that treatment
with tNP inhibited B-cell activation and differentiation into
antibody-producing cells.
Durability of the tNP Treatment Effect.Mice were injected s.c. with
tNP or saline admixed with OVA+CpG (days 0, 14, and 28) and
OVA (days 42, 56, 70, 84, and 98; Fig. 3A). Animals treated
concurrently with tNPs showed a substantial delay in the de-
velopment of anti-OVA antibodies, and the titers remained
∼37-fold lower than those observed in the immunized controls. Of
the 53 animals that were treated with tNP (nine independent
experiments), 15 showed no detectable titers and 38 showed low
titers at days 91–119 compared with animals in the untreated
group (Inset table in Fig. 3A). Only three animals (5%) of tNP-
treated animals showed titers greater than 2,000, compared with
59 animals (92%) in the control group. To test the durability of
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tolerance induced by tNP treatment, animals were given three
biweekly doses of tNPs concurrently with OVA+CpG immuniza-
tions and then boosted 14 times with OVA in the absence of
further tNP treatment (Fig. 3B). Anti-OVA titers in the tNP-
treated animals did not become detectable until day 58 and
remained ∼30–35-fold lower than that of untreated animals even
in the absence of tNP treatment between days 42–234. Anti-OVA
antibody titers remained well controlled in the tNP-treated ani-
mals even following challenge with OVA+CpG on days 239 and
253. Importantly, therapeutic administration of tNPs in mice with
preexisting anti-OVA antibody titers attenuated further boosting
with antigen even when the tNPs were coadministered with CpG
(Fig. 3C).
Antigen-Specific Tolerance Induction by tNP Administration.Animals
from Fig. 3B that had shown a long-lasting inhibition of anti-
OVA responses were immunized and boosted with keyhole
limpet hemocyanin (KLH). The tNP-treated mice showed a ro-
bust anti-KLH response (Fig. 4A) similar to that of the control
animals, indicating they were not chronically immunosuppressed.
To further test the specificity of the effect and show that the
immunosuppressive effects of rapamycin are not broad or sys-
temic, animals were injected s.c. with OVA+CpG ± tNP in the
right limbs and KLH+CpG in the left limbs (Fig. 4B). Mixing
tNP (containing OVA323–339 and rapamycin) with OVA+CpG
completely blocked the development of anti-OVA responses but
had no effect on the anti-KLH response initiated in the con-
tralateral limb (Fig. 4B). Moreover, a single injection of tNP
containing OVA and rapamycin administered 14 d before re-
peated immunization with pOVA and KLH selectively inhibited
the antibody response to OVA, but not KLH (Fig. 4C). In
contrast, pretreatment at day –14 with control NP[Rapa] had
no significant effect on the response to either OVA or KLH. In
addition, animals that were treated three times every 2 wk with
tNP+pOVA showed no detectable antibody response even at day
111 after five additional injections of pOVA in the absence of
additional tNP treatment (Fig. 4D). Naïve animals in which
pOVA immunizations were delayed until day 42 developed
a robust anti-OVA response by day 84 after three injections of
pOVA. These results further support the notion that tNP
treatment did not lead to systemic immunosuppression and in-
duced durable tolerance rather than merely delaying the immune
response.
tNP Trafficking. To determine the fate of tNP after injection in
vivo, cyanine 7 (Cy7) and Cy5 fluorescently labeled NPs were
developed. Whole-body imaging by 3D fluorescence-based to-
mography (34) showed that fluorescent NPs rapidly and selec-
tively accumulated in the liver and the spleen following i.v.
administration (Fig. 4E, Left and Fig. S1 A and B). In contrast,
fluorescent NPs administered s.c. in the hind limb showed rapid
and selective accumulation in the draining LNs (Fig. 4E, Right).
Immunohistochemical analysis of the spleen 24 h after i.v.
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Fig. 1. tNPs in the CD4+ T-cell response. (A) tNP platform. Modular, syn-
thetic, self-assembling tolerogenic PLGA NPs contain antigen and rapamycin.
(B) NPs containing antigen and rapamycin (but not antigen alone) are tol-
erogenic. OTII T cells were transferred into CD45.1 mice on day –2. At day 0,
animals received s.c. immunizations with vehicle (no immunization) or
OVA323–339 admixed with R848. At the same time, animals were injected i.v.
with saline (no treatment), empty NPs admixed with OVA323–339 (NP[Empty]+
OVA323–339), or tNPs (rapamycin+OVA323–339). Four days later, popLNs were
harvested and the total number of OTII T cells were quantified by flow
cytometry (n = 4 per group). Data are representative of two independent
experiments. (C) Encapsulation of rapamycin is critical for the control of CD4+
T-cell responses by tNP. OTII T cells were transferred into CD45.1+ mice
1 d before s.c. injection of tNPs (containing rapamycin and OVA323–339) or
NP[OVA323–339] alone or NP[OVA323–339] admixed with free rapamycin
(fRapa+NP[OVA323–339]). Seven days later, popLNs were harvested, and
total number of OTII cells was enumerated (Left) and the percentage of
Foxp3+CD25+ OTII T cells was determined (Right). Data are cumulative of
two independent experiments (n = 5). (D) Induction of antigen-specific
MHC class II-restricted CD4 T-cell tolerance using tNP. C57BL/6 mice were
treated i.v. on day –7 with NP[Rapa] or tNPs (rapamycin+OVA323–339). On
day –1, purified naïve CFSE-labeled CD4+OTII T cells were administered
i.v., and then mice were immunized with OVA323–339+R848 s.c. in the hind
limbs on day 0. On day 4, popLNs were harvested and analyzed as
in B. Data are representative of two independent experiments (n = 3 or
4 per group). All statistical analyses were performed using a one-way
ANOVA with a Bonferroni posttest (***P ≤ 0.001).
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injection of NP–Cy5 showed a typical distribution for a particu-
late antigen, colocalizing with the macrophages and DCs of the
red pulp and the marginal zone that delimits the white pulp (Fig.
4F). FACS analysis confirmed that most myeloid cells, including
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Fig. 2. tNPs in the humoral immune response. (A) Encapsulation of rapamycin is critical. C57BL/6 mice were injected s.c. on days 0, 14, and 28 with OVA+CpG
together with vehicle (no treatment), tNP (rapamycin+OVA323–339), free OVA323–339 (fOVA323–339), NP[OVA323–339] alone, or NP[OVA323–339] admixed with free
rapamycin (fRapa+NP[OVA323–339]). Animals were boosted with OVA on day 42, and anti-OVA IgG titers were determined by ELISA. Data are representative of
four independent experiments (n = 3–5). (B) Both peptide and protein formulations of tNP are effective. C57BL/6 mice were immunized s.c. in the hind limbs
on days 0, 14, and 28 with OVA+CpG and then boosted with OVA on days 42 and 56. In the Left andMiddle panels, animals were treated on days 0, 14, and 28
with tNP containing rapamycin and either OVA323–339 peptide or OVA protein, as indicated. Data are representative of three independent experiments (n =
5). In the Right panel, animals were treated s.c. in a distal site (front limb, f.l.) or i.v. with tNPs (OVA+rapamycin) or OVA-only NPs (NP[OVA]). The P values
represent the difference between the tNP-treated groups and the no-treatment groups. (C) Prevention of germinal center B cells with tNP. C57BL/6 mice were
injected i.v. with pOVA admixed with saline (no treatment) or tNP containing rapamycin and OVA323–339 on days 0 and 14. On day 21, splenocytes were
analyzed by flow cytometry for germinal center B cells (B220+CD19+TCRb– lymphocytes; n = 3, representative of two independent experiments). (D) Re-
duction of naïve B-cell activation with tNP. Cell trace violet-labeled MD4 B cells (5.106) were transferred i.v. into CD45.1+ animals. The next day mice were
dosed i.v. with saline, HEL-only NPs (NP[HEL]), or tNPs (rapamycin+HEL). Four days later, spleens were analyzed for MD4 B-cell proliferation. The plots show
the percentage of MD4 B cells that enter the cell cycle from the input (Left) and representative examples of the proliferation profile of each cell population
(Right). The results summarize three independent experiments (n = 2–3). The symbols and bars in all figures represent the geometric mean ± 95% confidence
interval. Statistics were performed using a one-way ANOVA with a Bonferroni posttest (****P ≤ 0.0001).
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macrophages, conventional DC (cDC), and plasmacytoid DC
(pDC), contained particles (Fig. S1C) (16, 30, 31). These results
show that our NPs efficiently deliver their payload to APCs in
the lymphoid organs.
Effects of tNP in Animal Models of Hypersensitivity. Animals re-
peatedly immunized i.v. with pOVA developed anaphylactoid
responses after three weekly i.v. infusions of pOVA, reminiscent
of the antibody-mediated hypersensitivity reactions observed in
some patients who develop antidrug antibodies (35–37). Un-
treated animals with high titers against OVA from Fig. 4C
exhibited strong hypersensitivity to pOVA administered i.v.,
whereas animals that received a single prophylactic treatment of
tNP showed no anti-OVA titers and were largely protected from
anaphylaxis (Fig. 5A). Similarly, animals immunized with OVA+
CpG and challenged with OVA s.c. experienced a significant
delayed-type hypersensitivity (DTH) response on the day after
challenge, whereas animals that received concomitant
tNP treatment during immunization showed no inflammation
(Fig. 5B). In addition, prophylactic treatment with tNP (con-
taining OVA+rapamycin) administered 4 d before immunization
to induce an anti-OVA CD8 T-cell response inhibited the sub-
sequent in vivo killing of labeled target cells loaded with
OVA257–264 (SIINFEKL), an MHC class I-restricted peptide of
OVA (Fig. 5C). Next, the efficacy of tNP was tested in animals
with allergic disorders. Animals treated with tNP during oral
(Fig. 5D) or i.p. sensitization (Fig. 5H) showed complete in-
hibition of both anti-OVA IgG and IgE antibody responses.
Immunization with OVA and aluminum hydroxide gel (Alum) i.
p. followed by intragastric (i.g.) or intranasal (i.n.) challenge with
OVA induced the development of oral allergy or allergic airway
inflammation, respectively. Sensitized animals treated thera-
peutically with tNP i.v. at the time of oral challenge showed
a reduction in anaphylaxis (sickness score, diarrhea, and tem-
perature drop; Fig. 5E). Serum levels of mouse mast cell pro-
tease 1 (mMCP1) in recently challenged animals were also
reduced by prior treatment with tNP (Fig. 5F). No effect was
observed on the levels of serum anti-OVA IgE concentration
using this therapeutic protocol. In animals with allergic airway
inflammation induced by challenge with OVA i.n. (Fig. 5G),
therapeutic tNP treatment after establishment of the allergic
reaction reduced the number of lymphocytes (CD8+ and CD4+
T cells and B cells) and eosinophils in the bronchoalveolar la-
vage (BAL) fluid. Treatment with tNPs also resulted in de-
creased numbers of splenic T cells with an activated phenotype
(CXCR5+TCRβ+CD19–CD45R–) and an increased proportion
of cells with a B regulatory phenotype (CD19+CD45R+IL-10+)
compared with saline-treated animals. Similar to animals with
oral allergies, no significant effect was observed on the IgE levels
using this therapeutic protocol (Fig. 5G). However, concurrent
treatment with tNP during immunization (days, 0, 7, and 14)
suppressed the IgE response and completely blocked the re-
cruitment of lymphocytes to the airways in the presence of OVA
(Fig. 5H). Importantly, no adverse events were observed even when
tNPs were administered i.v. to animals with high serum levels of
antigen-specific IgG and/or IgE. Together these results show that
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Fig. 3. Sustained and robust control of antibody
responses with tNP. (A) Long-term effect of tNP.
C57BL/6 animals were immunized s.c. with OVA+
CpG on days 0, 14, and 28 and boosted with OVA
every 14 days until at least day 77 with or without
tNP (containing rapamycin+OVA323–339). The figure
depicts the anti-OVA IgG titers for the indicated
range of days. Each dot represents the average titer
for each group taken from nine independent
experiments (n = 51 and 53 animals per group). The
table shows the number of animals in each group
with the indicated level of anti-OVA titers at the last
bleed day (between day 91 and day 119). (B) Dura-
bility of tNP therapy. Mice were immunized s.c. with
OVA+CpG and treated i.v. with vehicle (no treat-
ment) or tNP (rapamycin+OVA323–339) on days 0, 14,
and 28. Animals were boosted with OVA every 14
d from day 42 to day 224 without any further tNP
treatment. The treated group received another in-
jection of tNP on day 234. The animals were sub-
sequently challenged with OVA+CpG s.c. on days
239 and 253, followed by a boost of OVA s.c. on day
267 (n = 5). (C) Therapeutic tNP treatment inhibits
further boosting of antigen titers. Animals were
immunized s.c. with OVA+CpG on days 0 and 14
without any treatment. At day 21, anti-OVA titers
were measurable in all animals. The untreated
control group continued to receive injections of
OVA+CpG every 2 wk from days 28–213, whereas the
treated group received biweekly OVA+CpG supple-
mented with tNP (rapamycin+OVA323–339) starting at
day 21. EC50 was determined by ELISA (n = 5). The
symbols represent the geometric mean ± 95% con-
fidence interval. Statistics were performed using
a two-way ANOVA with a Bonferroni posttest
(****P ≤ 0.0001).
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treatments with tNP during or after sensitization are safe and
can significantly reduce inflammatory processes associated with
hypersensitivity reactions.
Prophylactic and Therapeutic Efficacy of tNP in a Relapsing–Remitting
Model of Experimental Autoimmune Encephalomyelitis. Empty NP
or tNP containing rapamycin and PLP139–151 were administered
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Treatment with tNP does not result in broad immunosuppression. C57BL/6 mice were immunized with OVA+CpG in the right (front and hind) limbs and with KLH
+CpG in the left limbs, whereas treated animals received OVA+CpG+tNP injections in the right limbs and KLH+CpG in the left limbs every 2 wk for 8 wk. Anti-OVA
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anti-KLH titers were assessed on day 41. The results summarize three independent experiments (n = 5). (D) Durability of prophylactic induction of antigen-specific
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animals was delayed until day 42 (delayed immunization control). In all figures and panels, the bars and the symbols represent the geometric mean ± 95%
confidence interval (n = 5). All P values were calculated using a Bonferroni posttest of a regular one-way or two-way ANOVA test (***P ≤ 0.001). (E) In vivo
trafficking of tNP. (Left) (i.v. injection) Balb/C animals were immunized with pOVA on days –27 and –13. On day 0, fluorescently tagged Cy7–tNP containing OVA
and rapamycin were injected i.v., and the animals were imaged by 3D FMT at 6 h after injection. (Right) (s.c. injection) Naïve Balb/C mice were injected with
fluorescently tagged Cy7–tNP s.c. and then imaged 1 h after injection (n = 3). I, iliac; P = popLNs; R, renal. (F) Cellular localization of tNP. Fluorescently tagged NP–
Cy5 (red) NPs were injected i.v., and spleens were harvested 24 h later for cryosectioning and immunohistochemical analysis. Shown are representative low and
high (Lower Right panel) magnification (10× and 100×, respectively) photomicrographs of the distribution of the NPs among the red pulp (RP), the white pulp
(WP), and the marginal zone (MZ) delineated by the localization of macrophages (MPs, F4/80, green), DCs (CD11c, dark blue), and B cells (B220, cyan).
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class I-restricted OVA peptide OVA257-264 SIINFEKL and labeled control cells. The next day, spleens were harvested and specific lysis of target cells was de-
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83 (n = 5). (E) Inhibition of anaphylactic response to an oral allergen. Balb/C mice were immunized with OVA+Alum on days 0 and 14 and challenged six times
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challenge. Mock immunized animals received Alum. Animals were assessed by three blinded scorers for anaphylaxis, and the percent of animals with diarrhea.
The changes in body temperature were also recorded. Anti-OVA IgE was assessed on day 38. Data are representative of two independent experiments (n = 5).
(F) Inhibition of mMCP1 release. Balb/C animals were immunized with OVA+Alum and then challenged orally with OVA while receiving treatment with tNPs.
Serum mMCP1 levels were assessed 1 h after the last (sixth) challenge by ELISA (n = 5). (G) Effect of therapeutic treatment with tNP on allergic airway in-
flammation. Balb/C animals were injected with OVA+Alum on days 0 and 5 and then challenged with OVA i.n. on days 12, 13, and 14. A sentinel group of
animals killed on day 15 were confirmed to have allergic airways. At days 18, 25, and 32, animals received i.v. treatments of saline, NP[OVA323–339], or tNPs
(rapamycin+OVA323–339). BAL fluid was collected after challenge and assessed for T cells, B cells, and eosinophils. Splenocytes were restimulated overnight with
OVA and assessed for TCRβ+CXCR5+ T cells and CD19+B220+IL-10+ cells (Bregs). (H) Inhibition of IgE responses and airway reactivity using tNP. BALB/c animals
were injected with OVA+Alum on days 0, 7, and 14 and then challenged daily with OVA i.n. from day 21–24. Animals were treated i.v. with saline (no
treatment), NP[OVA323–339], or tNP (rapamycin+OVA323–339) on days 0, 7, and 14. The results are representative of two independent experiments
(n = 5). The bars in all figures and panels represent the geometric mean (±95% confidence interval). All P values were calculated using a Bonferroni
posttest of a regular one-way or two-way ANOVA test (***P ≤ 0.001).
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prophylactically to SJL mice by s.c. injection 21 and 14 d be-
fore immunization with PLP139–151/CFA to induce relapsing–
remitting experimental autoimmune encephalomyelitis (R-EAE).
Treatment with tNP inhibited the onset and severity of paralysis
typical of this model of autoimmunity (Fig. 6A and Fig. S2A) and
inhibited weight loss (Fig. S2). The animals were followed for
3 wk to exclude the possibility of a delayed response. Mice treated
with NP[Rapa] showed only a modest delay in disease onset,
whereas animals treated with NP containing only the PLP139–151
peptide showed partial protection. Importantly, animals treated
therapeutically with a single i.v. injection of tNP administered
near the peak of disease showed complete inhibition of disease
relapse (Fig. 6B and Fig. S2B). Therapeutic treatment with tNP
by s.c. injection resulted in complete inhibition of relapse in 12
of 13 mice (Fig. 6B).
Induction of Tolerance to FVIII in Hemophilia A Mice. Hemophilia A
mice deficient in the expression of FVIII (E16) present with
similar defects in blood clotting and propensity to develop neu-
tralizing antibodies against recombinant human FVIII (rhFVIII)
as severe hemophilia A patients. Administration of rhFVIII
led to the development of neutralizing antibody responses or
“inhibitors” that block the procoagulant function of the thera-
peutic rhFVIII, similar to previous studies (38). Prophylactic
administration of tNPs given at the same time as rhFVIII ad-
ministration in naïve mice (Fig. 6C) or therapeutic administra-
tion of tNPs in mice previously primed with three injections of
rhFVIII led to a significant reduction of anti-FVIII antibodies,
including neutralizing antibodies (Fig. 6D).
Discussion
We were guided by the following design criteria in developing
tNPs: (i) use of a polymer (PLGA) that is biocompatible, bio-
degradable, and used in multiple products licensed for clinical
use by regulatory agencies, (ii) a small-molecule immunomodu-
latory agent (rapamycin) that has been validated in humans and
is capable of securing immune tolerance programming even in
the face of inflammatory signals, (iii) nano-sized particles to al-
low for efficient transport to lymphoid organs and capture by
APCs, and (iv) concomitant delivery of either protein or peptide
antigens with the small-molecule immunomodulator, thus enabling
coordinated delivery of immunological instructions to APCs. Im-
portantly, we have previously validated the manufacturing process
for PLGA NPs through the successful production of multiple
GMP lots that were released and used in a phase 1 vaccine
clinical trial (39).
We show here that the tNPs are capable of inducing antigen-
specific B-cell tolerance that is maintained for at least 200 d in
the face of repeated challenges with antigen (Fig. 3B). Treat-
ment with tNPs through a variety of routes (i.v. and s.c.) and
schedules of treatment efficiently inhibited B-cell activation and
antibody responses against antigens administered locally or sys-
temically (i.v., s.c., i.g., and i.p.; Figs. 2 B–D, 4C, and 5) as well as
local and systemic hypersensitivity reactions (Fig. 5 A, B, and E).
Importantly, tNPs were capable of inducing tolerance even when
coadministered with free antigen in the presence of potent TLR
agonists, such as CpG or R848, and adjuvants, such as Alum and
CTx (Figs. 1B, 3 A and B, and 5). Prophylactic administration of
tNPs inhibited anti-OVA IgE antibody production in allergy
models (Fig. 5 D and H). Therapeutic treatment had no effect on
anti-IgE levels but attenuated the pathological effects of antigen
administration in a model of oral allergy (Fig. 5E) and allergic
airway inflammation (Fig. 5G). These results suggest that the
beneficial effects mediated by tNP treatment after immunization
could be exerted on the cellular compartment responding to the
antigen rather than on the antibody levels per se. It is possible
that therapeutic reduction of preexisting antibody levels would
require more time due to the presence of long-lived plasma cells.
However, therapeutic administration of tNPs applied on preex-
isting anti-OVA IgG responses and inhibited further boosting
with the antigen even in the presence of CpG (Fig. 3C), sug-
gesting an inhibitory effect on the memory cells responsible for
the secondary or boost response. We believe that there are both
temporal and spatial aspects to the induction of antigen-specific
immune tolerance with tNPs. The temporal aspect of tolerance
induction is illustrated in Fig. 4C, where tNPs are administered
14 d before repeated immunization with OVA and KLH. In this
experiment, the tNP containing OVA and rapamycin selectively
inhibits the antibody response to OVA but not KLH, whereas
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Fig. 6. Induction of tolerance in R-EAE and hemophilia A mice using tNP.
(A) Prophylactic treatment of EAE. SJL mice (n = 12) were treated pro-
phylactically i.v. with tNP (PLP139–151 and rapamycin) or placebo NPs (NP
[Empty]) on day –21 and –14. R-EAE was induced by injecting PLP139–151+CFA
and pertussis toxin (PTx) on day 0. EAE disease symptoms were scored by
blinded observers. (B) Therapeutic treatment of EAE. EAE was induced in SJL
mice (n = 13–14 per group) by injecting PLP139–151/CFA. Animals were in-
dividually monitored for onset of disease and treated therapeutically on the
third day of detectable disease (around day 13) with either empty NP or tNP.
Results are represented as the mean ± 95% confidence interval. For statis-
tical analysis, Student t test with two-tailed distribution was used (****P <
0.0001). (C) Inhibition of anti-FVIII responses in naïve hemophilia A mice.
FVIII KO hemophilia A mice (E16, n = 8 at day 0) received five weekly i.v.
injections of rhFVIII together with tNP (rapamycin+FVIII peptides), empty
NPs, or IVIG. The mice were then challenged with 1 μg of FVIII on days 57 and
81 without treatment. Anti-FVIII antibody levels (day 95) were determined
by ELISA. (D) Therapeutic efficacy of tNP treatment on anti-FVIII and in-
hibitor titers in E16 mice. Hemophilia A mice received three weekly i.v.
injections of rhFVIII. Anti-FVIII antibody levels were determined on day 23,
and primed E16 mice were then assigned into two groups. Starting on day
29, one group of the mice received two rounds of five weekly i.v. injections
of rFVIII+tNP (rapamycin+FVIII peptides). The control group received rhFVIII+
NP[Empty]. The data show the anti-FVIII antibody levels 2 wk after the last
therapeutic injection (day 127). Anti-FVIII titers were quantified using
a standard curve generated with a mixture of monoclonal anti-FVIII A2 and
C2 antibodies, whereas FVIII inhibitor titers (BU/mL) were determined using
a modified Bethesda assay. Data are expressed as mean ± SEM. For statistical
analysis, Student t test with two-tailed distribution was used (**P < 0.01).
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NPs containing only rapamycin have no effect on either re-
sponse. In contrast, Fig. 4B illustrates the spatial aspect of an-
tigen-specific tolerance induction, where tNP and OVA+CpG
are administered in the left flank and KLH+CpG is administered
at the same time in the right flank. Because the tNP bio-
distribution following s.c. administration is localized to the
draining LNs (Fig. 4E, Right), the tNP selectively inhibits the
immune reaction against OVA in the LNs, draining the left flank
without affecting the immune response to KLH in the right flank.
The precise mechanism of action of our tNPs remains to be
determined. Nanoparticulates have been shown to be selectively
endocytosed by APCs, such as macrophages and DCs (16, 30,
31). The codelivery of antigen and rapamycin provide an in-
struction set that could allow for the conditioning of tolerogenic
DCs capable of inducing CD4+ Treg (22, 23). In support of this
notion, prophylactic treatment with OVA323–339–loaded tNPs 7 d
before transfer of OTII T cells resulted in complete inhibition
of OTII T-cell expansion in response to immunization with
OVA323–339+R848, whereas treatment with control NPs con-
taining only rapamycin had no effect (Fig. 1D). These experi-
ments show that the inhibitory effect induced by the tNPs is more
durable than that expected from transient immunosuppression
by rapamycin and is dependent on the presence of antigen, in-
dicating the formation of OVA323–339–specific regulatory cells
that can control the activation of the subsequently transferred
OTII T cells. Indeed, tNP treatment induced an increase in the
percentage of FoxP3+ antigen-specific T cells (Fig. 1B). Im-
portantly, we found that admixing free rapamycin with NP-
encapsulated OVA (or OVA323–339) did not result in immune
tolerance. In fact, free rapamycin, administered at an equivalent
dose as that used in tNP treatment, showed the opposite trend
with respect to inhibition of OVA-specific T-cell expansion and
induction of antigen-specific Tregs, perhaps due to the direct
effect of free rapamycin on enhancing effector memory T-cell
formation (40). Moreover, free rapamycin showed a consistent
trend toward enhancing anti-OVA–specific antibody responses.
Similarly, NPs loaded with protein antigen in the absence of
rapamycin were very immunogenic. These results indicate that
the biology of both the rapamycin and the antigen can be pro-
foundly influenced by the context in which they are delivered.
Tolerance induction using NPs was also demonstrated by Yeste
et al. (19), using gold NPs loaded with 2-(1′H-indole-3′-carbonyl)-
thiazole-4-carboxylic acid methyl ester (or ITE, a ligand for the aryl
hydrocarbon receptor) and MOG35–55 (MHC class II-restricted
peptide from myelin oligodendrocyte glycoprotein) in a model of
EAE. In contrast, Getts et al. (13) demonstrated tolerogenic activity
of PLP139–151 conjugated to polystyrene or PLGA microparticles in
the absence of any immunomodulator. Induction of tolerance with
NPs containing only antigen was not observed by us (Fig. 2B) or by
Yeste et al. (19). However, the larger, highly negatively charged
particles used by Getts et al. (13) may induce tolerance through an
alternative mechanism via MARCO+ macrophages.
One of the potential risks of antigen-based immunotherapy is
that administration during an ongoing inflammatory event could
potentially override tolerogenic programming, resulting in dis-
ease exacerbation. This is a phenomenon well known in allergy
immunotherapy in which administration of the antigen can result
in adverse events, including anaphylaxis (41). We have attempted
to mitigate this risk by using an immunomodulatory agent,
rapamycin, which can induce and maintain the tolerogenic
programming, even in the presence of potent TLR agonists.
Another potential advantage of our tNPs is the ability to
incorporate whole protein antigen, which is an important con-
sideration for clinical application in a heterogeneous human
population, particularly for large complex proteins, like FVIII,
that contain many MHC class II epitopes. NPs containing pro-
tein antigen without rapamycin are immunogenic (Fig. 2 B and
D), whereas the encapsulation of rapamycin in the NPs, but not
admixed free rapamycin, induces tolerance. To our knowledge,
the only other NPs capable of presenting and inducing tolerance
to whole protein antigens are the liposomes bearing the CD22
ligand described by Macauley et al. (18), which induce B-cell, but
not T-cell, tolerance. Finally, it is notable that our tNPs are ca-
pable of inhibiting immune responses when administered either
i.v. or s.c., whereas other NP approaches appear to be limited to
systemic administration (13, 19, 32). More experimentation is
necessary to compare these technologies and determine whether
they can be used in similar applications.
The emergence of NP-based therapies for the induction of
antigen-specific immune tolerance holds considerable promise
for the future of immunotherapy. Tolerogenic therapies could be
beneficial for the treatment of allergic asthma, life-threatening
food allergies, and autoimmune disease (8). A single therapeutic
dose of tNP administered at the peak of disease completely
inhibited disease relapse in EAE, a model of human multiple
sclerosis (Fig. 6B). Antigen-specific tolerance could be useful in
preventing antidrug antibodies, which can compromise efficacy
and safety of biologics. A prominent example is the neutralizing
antibody responses to FVIII, which results in major complica-
tions for up to 30% of hemophilia A patients (42). Currently
patients that develop inhibitors are treated with large and fre-
quent doses of FVIII, which is extremely costly. Here we show
that adding tNP to the therapeutic regimen of FVIII for a limited
number of injections allows for the establishment of tolerance
(Fig. 6 C and D). Protein therapies are the fastest growing
segment of new drug approvals, and a proliferation of novel
engineered proteins, such as multivalent antibodies and anti-
body-drug conjugates, may be at increased risk for immunoge-
nicity (43). tNPs could potentially also be applied to prevent
immunogenicity associated with vectors used for gene therapy.
The ability to translate antigen-specific therapy to human clinical
practice would represent a breakthrough that could potentially
benefit patients across a wide spectrum of clinical indications.
Materials and Methods
Complete details of materials are provided in SI Materials and Methods.
tNP and NP Manufacturing. tNPs containing both antigen and rapamycin were
prepared using a water-in-oil-in-water double emulsion solvent evaporation
method (44, 45). Briefly, PLGA, pegylated polylactic acid (PLA-PEG), and
rapamycin were dissolved in dichloromethane to form the oil phase. An
aqueous solution of antigen (OVA protein, OVA323–339 peptide, FVIII75–89
peptide, FVIII1723–1737 peptide, FVIII2191–2210 peptide, or PLP139–151 peptide)
was then added to the oil phase and emulsified by sonication (Branson
Digital Sonifier 250A). Following emulsification of the antigen solution into
the oil phase, a double emulsion was created by adding an aqueous solution
of polyvinylalcohol and sonicating a second time. The double emulsion was
added to a beaker containing phosphate buffer solution and stirred at room
temperature for 2 h to allow the dichloromethane to evaporate. When
creating NPs containing rapamycin but no antigen, or NPs without any encap-
sulated agents, a similar oil-in-water single emulsion process was used. The
resulting NPs were washed twice by centrifuging at 75,600 × g and 4 °C followed
by resuspension of the pellet in PBS. Fluorescent Cy5- and Cy7-containing NPs
were manufactured as described above using PLGA–Cy5 or PLGA–Cy7 conjugate,
respectively. PLGA with a butyl amine end group was prepared from PLGA–acid,
which was then treated with Cy7–acid or Cy5–acid in the presence of a coupling
agent (O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate) to
afford the conjugates.
Animal Models. Animal procedures involving hemophilia A mice, EAE, and in
vivo imaging were approved by the Institutional Animal Care and Use
Committee of the Uniformed Services University of the Health Sciences,
Hooke Laboratories, and Molecular Research Imaging, respectively. All other
mouse experiments were approved by the Institutional Animal Care and Use
Committee of Avastus Preclinical Services, following local and national
guidelines and regulations.
Relapsing EAE model. EAE was induced by injection of SJL mice s.c. at four sites
in the back with PLP139–151 emulsified in CFA (Hooke Laboratories) followed
2 h later by i.p. injection of 154 ng of pertussis toxin. Blinded EAE scores
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were assessed daily starting from day 7, and body weight was measured
three times per week. EAE was scored on a 0–5 scale as follows: 0, no obvious
changes in motor functions of the mouse in comparison with nonimmunized
mice; 1, limp tail; 2, limp tail and weakness of hind legs; 3, limp tail and
complete paralysis of hind legs (most common) or limp tail with paralysis
of one front and one hind leg; 4, complete hind leg and partial front leg
paralysis; 5, death or euthanized because of severe paralysis.
Allergic airway model. BALB/c female mice aged 8–10 wk were sensitized by i.p.
injections of 10 μg Ova adsorbed to 4 mg of Alum on days 0 and 5. On days 7,
8, and 9, mice were administered 25 μg Ova i.n. Mice were treated with tNP
or PBS on days 25, 32, and 39. Finally, mice were administered PBS for the
control group or 25 μg OVA i.n. for 3 consecutive days from days 46–48 and
were killed 1 h after the last challenge by a lethal dose of isofluorane. Lungs
were lavaged three times with 1 mL of ice-cold PBS containing 3 mM EDTA.
Oral allergy model. BALB/c female mice were sensitized by i.p. injections
of 500 μg OVA adsorbed to 4 mg of Alum on day 0 and then 50 μg OVA
adsorbed to 4 mg of Alum on day 14. On days 27, 29, 31, 34, and 36, mice
were treated i.v. with tNP or PBS and challenged with 50 mg of OVA by i.g.
gavage. Mice were evaluated for sickness by three blinded scorers as pre-
viously described (46, 47). Rectal temperatures and liquid stool scores
were measured (0, dry; 1, wet) 1 h after the final challenge.
In vivo CTL assay. Test animals were immunized with NPs containing OVA
protein and CpG oligodeoxynucleotides (ODN). Five days later, spleen cells
harvested from naïve animals were loaded with low levels of carboxy-
fluorescein diacetate succinimidyl diester (CFSE) and the OVA257–264 MHC
class I-restricted peptide of OVA (CFSElow, SIINFEKL+ Targets), whereas
another portion of cells were loaded with high levels of CFSE alone (CFSEhigh,
SIINFEKL− Control). A 1:1 mixture of these labeled target cells was injected
into the recipient naïve and test animals to monitor specific killing of SIIN-
FEKL peptide-presenting cells (CFSElow) relative to their control (CFSEhigh).
In Vivo FMT Imaging. In vivo 3D fluorescence tomography (FMT) imaging was
performed by Molecular Imaging on the Perkin-Elmer FMT 2500 LX Quantitative
Tomography Imaging System. Mice were injected with Cy7-labeled NPs and
anesthesitized with 2% (vol/vol) isoflurane gas just before imaging. A scanning
region was manually positioned over the body from the head to chest for scan
1 and from chest to hind limbs for scan 2. Each animal was scanned in that
specific region of interest using a medium (3 mm) source density. Images were
reconstructed and analyzed using Perkin-Elmer True Quant software.
Fluorescence Imaging. Frozen sections were fixed with cold acetone and
stained for the indicated markers and visualized at room temperature using
an upright epifluorescencemicroscope Leica DMI6000B system equippedwith
a Leica DFC340FX. Images were processed using ImageJ software.
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